Share Prices & Company Research

Market News

16 Jan 2019 | 08:33

EKF Diagnostics expects earnings to 'comfortably' top market expectations

EKF Diagnostics said Wednesday it expected adjusted earnings (EBITDA) would be 'comfortably ahead' of market expectations as it continued to make significant progress on in delivering on its strategy. 'The company announces that adjusted EBITDA for the year ended 31 December 2018 is expected to be comfortably ahead of market expectations,' EKF said. Cash generation in the second half had been 'very strong' with net cash at the end of the year of £9.4m, up from £7.0m last year, following the £3.1m investment in Renalytix AI and share buybacks of almost £0.9m, the company said.

The outlook in 2019 was 'positive' as the company aimed to benefit from the groundwork laid in 2018, including a full-year contribution from the OEM contract with McKesson-Surgical for the distribution of Diaspect Tm in the US and the enzyme business with Oragenics.

At 8:33am: (LON:EKF) EKF Diagnostics Holdings PLC share price was +2.25p at 33.55p

Story provided by
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.